Neuronostics develops BioEP™, a cloud-based decision support tool that utilizes mathematical modeling to analyze EEG data for identifying biomarkers associated with epilepsy. This technology enhances diagnostic accuracy and speed, enabling clinicians to make informed decisions from the first EEG, even in cases without visible epileptiform activity.
Funding
$2.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional EEG interpretation for epilepsy diagnosis is limited by subjective analysis and the frequent absence of visible epileptiform activity, leading to diagnostic delays and uncertainty for clinicians. This can result in delayed treatment and prolonged patient anxiety.
Solution
Neuronostics' BioEP™ is a cloud-based decision support tool that applies mathematical modeling to EEG data, identifying novel biomarkers associated with epilepsy. By analyzing EEG data for specific features and brain network-based markers, BioEP™ enhances diagnostic accuracy and speed, even in EEGs lacking visible epileptiform activity. This technology supports clinicians in making informed decisions from the first EEG, facilitating faster and more accurate diagnoses and informing optimal care pathways. BioEP™ aims to improve the efficiency of epilepsy diagnostics, empowering healthcare providers to deliver better care, faster diagnoses, and improved patient outcomes.
Target Audience
The primary target audience includes neurologists, epileptologists, and healthcare providers involved in epilepsy diagnosis and management.
Features
- Cloud-based platform accessible from any location
- Mathematical modeling of EEG data to identify subtle biomarkers
- Analysis of brain network-based markers indicative of epilepsy
- Support for diagnosis from the first EEG, even without visible epileptiform activity
- Identification of data features elevated in people with epilepsy